Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Huilin Ye

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8041-4056; OpenAlex author ID A5051815365. Sources: OpenAlex.

Their work

Papers
23 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2014: 1 paper · 2015: 5 papers · 2016: 1 paper · 2017: 3 papers · 2018: 3 papers · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 4 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 23

  1. Extracellular Volume Fraction Combined With Pathological Features of α-SMA and FAP for Predicting the Prognosis of Patients With Pancreatic Ductal Adenocarcino… Co-author DOI 10.1002/cam4.71281↗
  2. Corrigendum to "LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9" [Canc. Lett. 410 (2017) 68-81]. Co-author DOI 10.1016/j.canlet.2022.215836↗
  3. Corrigendum to "Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in … Co-author DOI 10.1016/j.canlet.2022.215859↗
  4. Corrigendum to "Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer" [Canc. Lett. 459(2019)204-215]. First author DOI 10.1016/j.canlet.2022.215897↗
  5. Correction: lncRNA-PLACT1 sustains activation of NF-κB pathway through a positive feedback loop with IκBα/E2F1 axis in pancreatic cancer. Co-author DOI 10.1186/s12943-022-01585-x↗
  6. Correction: Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. First author DOI 10.1038/s41419-021-03420-5↗
  7. lncRNA-PLACT1 sustains activation of NF-κB pathway through a positive feedback loop with IκBα/E2F1 axis in pancreatic cancer. Co-author DOI 10.1186/s12943-020-01153-1↗
  8. Tumor-neuroglia interaction promotes pancreatic cancer metastasis. Co-author DOI 10.7150/thno.42440↗
  9. Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer. First author DOI 10.1016/j.canlet.2019.06.005↗
  10. Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Co-author DOI 10.1038/s41467-019-09712-x↗
  11. FEZF1-AS1/miR-107/ZNF312B axis facilitates progression and Warburg effect in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-017-0052-1↗
  12. Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0486-0↗
  13. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. First author DOI 10.1038/s41419-018-1104-x↗
  14. LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9. Co-author DOI 10.1016/j.canlet.2017.09.019↗
  15. Endogenous miRNA Sponge LincRNA-ROR promotes proliferation, invasion and stem cell-like phenotype of pancreatic cancer cells. Co-author DOI 10.1038/cddiscovery.2017.4↗
  16. HIF-2α regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jcmm.13202↗
  17. Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-rela… Co-author DOI 10.1016/j.canlet.2015.12.010↗
  18. Analysis of global gene expression profiles suggests a role of acute inflammation in type 3C diabetes mellitus caused by pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00125-014-3481-8↗
  19. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. Co-author DOI 10.1186/s12967-015-0442-z↗
  20. Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy. Co-author DOI 10.18632/oncotarget.5150↗
  21. Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers. Co-author DOI 10.18632/oncotarget.5533↗
  22. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival. Co-author DOI 10.3748/wjg.v21.i21.6621↗
  23. Macrophage migration inhibitory factor is overexpressed in pancreatic cancer tissues and impairs insulin secretion function of β-cell. Co-author DOI 10.1186/1479-5876-12-92↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shangyou Zheng · 18 shared papers, 2015–2022 · strength 1.49
  2. Quanbo Zhou · 17 shared papers, 2014–2022 · strength 1.31
  3. Zhiqiang Fu · 15 shared papers, 2014–2022 · strength 1.07
  4. Rufu Chen · 11 shared papers, 2015–2022 · strength 0.93
  5. Yimin Liu · 11 shared papers, 2015–2022 · strength 0.75
  6. Guolin Li · 9 shared papers, 2016–2022 · strength 0.74
  7. Changhao Chen · 7 shared papers, 2017–2022 · strength 0.72
  8. Lusheng Wei · 8 shared papers, 2017–2022 · strength 0.69
  9. Zhihua Li · 7 shared papers, 2017–2022 · strength 0.63
  10. Xiaohui Zhao · 9 shared papers, 2015–2022 · strength 0.61
  11. Rufu Chen · 6 shared papers, 2015–2021 · strength 0.50
  12. Yuming Luo · 5 shared papers, 2016–2022 · strength 0.48
  13. Wenzhu Li · 6 shared papers, 2015–2022 · strength 0.40
  14. Wenchao Gao · 7 shared papers, 2014–2022 · strength 0.37
  15. Yingxue Wang · 5 shared papers, 2015–2022 · strength 0.34
  16. Rufu Chen · 4 shared papers, 2014–2022 · strength 0.26
  17. Zhihua Li · 4 shared papers, 2015–2022 · strength 0.25
  18. Yue Zhao · 3 shared papers, 2017–2022 · strength 0.25
  19. Xiaofan Ren · 2 shared papers, 2020–2022 · strength 0.25
  20. Mingyang Liu · 2 shared papers, 2020–2022 · strength 0.25
  21. Wenbin Li · 1 shared paper, 2025 · strength 0.25
  22. Liqiang Liu · 1 shared paper, 2025 · strength 0.25
  23. Langping Tan · 4 shared papers, 2014–2022 · strength 0.24
  24. Chonghui Hu · 2 shared papers, 2019–2022 · strength 0.22
  25. Bin Zhang · 2 shared papers, 2019–2022 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.